Engineered CAR-T cells show promise against glioblastoma in preclinical models

Engineered immune cells target and destroy glioblastoma in animal models

With a five-year survival rate of less than 5%, glioblastoma is one of the most aggressive types of brain cancer. Until now, all available treatments, including immunotherapy—which involves strengthening the immune system to fight cancer—have proved disappointing. CAR-T cells are genetically modified immune cells manufactured in the laboratory and designed to identify and destroy cancer cells.

Engineered CAR-T cells show promise against glioblastoma in preclinical models

With a five-year survival rate of less than 5%, glioblastoma is one of the most aggressive types of brain cancer.

New Multi-Target CAR-T Cells Eradicate Glioblastoma in Preclinical Models

With a five-year survival rate of less than 5%, glioblastoma is one of the most aggressive types of brain cancer.

Montefiore Einstein Director Edward Chu dies of glioblastoma at 66

Edward Chu was an expert in pharmacology whose research improved therapies for colorectal cancer, leading to the identification of new treatment targets and driving scientific advances in the field.  His understanding of cancer centers—how they are structured and how they operate—led many institutions to reach their highest potential. His ability to make complicated concepts seem […]